The HIV giant is expected to announce its fiscal second-quarter earnings for 2026 in the near term. More News from BarchartFor the full year, analysts expect GILD to report loss per share of $0.77, down 109.5% from EPS of $8.15 in fiscal 2025. GILD stock has outperformed the S&P 500 Index's ($SPX) 18.2% gains over the past 52 weeks, with shares up 23.1% during this period. Analysts' consensus opinion on GILD stock is bullish, with a "Strong Buy" rating overall. Out of 30 analysts covering the stock, 22 advise a "Strong Buy" rating, two suggest a "Moderate Buy," and six give a "Hold."